BlackRock
OTLK icon

BlackRock’s Outlook Therapeutics OTLK Stock Holding History

BlackRock’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
1,668,579
+1,191,108
+249% +$739K ﹤0.01% 4087
2026
Q1 		$98.3K Buy
477,471
+72,929
+18% +$31.5K ﹤0.01% 4964
2025
Q4 		$639K Buy
404,542
+34,808
+9% +$55.6K ﹤0.01% 4428
2025
Q3 		$392K Buy
369,734
+29,838
+9% +$51.6K ﹤0.01% 4523
2025
Q2 		$544K Sell
339,896
-902,476
-73% -$1.44M ﹤0.01% 4420
2025
Q1 		$1.52M Buy
1,242,372
+148,850
+14% +$261K ﹤0.01% 4075
2024
Q4 		$2.07M Buy
1,093,522
+48,534
+5% +$200K ﹤0.01% 4025
2024
Q3 		$5.58M Buy
1,044,988
+381,492
+57% +$2.79M ﹤0.01% 3651
2024
Q2 		$4.9M Buy
663,496
+159,508
+32% +$1.28M ﹤0.01% 3697
2024
Q1 		$6.02M Sell
503,988
-14,326
-3% -$116K ﹤0.01% 3601
2023
Q4 		$4.08M Buy
518,314
+48,643
+10% +$411K ﹤0.01% 3766
2023
Q3 		$2.08M Buy
469,671
+8,881
+2% +$196K ﹤0.01% 3980
2023
Q2 		$16M Buy
460,790
+57,419
+14% +$1.57M ﹤0.01% 3172
2023
Q1 		$8.79M Buy
403,371
+51,071
+14% +$1.14M ﹤0.01% 3378
2022
Q4 		$7.61M Buy
352,300
+9,475
+3% +$206K ﹤0.01% 3521
2022
Q3 		$8.36M Sell
342,825
-4,955
-1% -$115K ﹤0.01% 3521
2022
Q2 		$7.09M Buy
347,780
+13,774
+4% +$396K ﹤0.01% 3665
2022
Q1 		$11.9M Buy
334,006
+38,068
+13% +$1.19M ﹤0.01% 3480
2021
Q4 		$8.05M Buy
295,938
+4,007
+1% +$143K ﹤0.01% 3789
2021
Q3 		$12.7M Buy
291,931
+4,234
+1% +$204K ﹤0.01% 3572
2021
Q2 		$14.3M Buy
287,697
+200,570
+230% +$9.3M ﹤0.01% 3493
2021
Q1 		$3.92M Buy
+87,127
New +$3.34M ﹤0.01% 4046
2018
Q2 		– Sell
-194
Closed -$27K – 5057
2018
Q1 		$27K Sell
194
-5
-3% -$893 ﹤0.01% 4526
2017
Q4 		$41K Buy
199
+8
+4% +$1.66K ﹤0.01% 4465
2017
Q3 		$41K Sell
191
-11
-5% -$2K ﹤0.01% 4508
2017
Q2 		$32K Buy
+202
New +$57.1K ﹤0.01% 4588

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's OTLK Position: Q2 2026 in Review

BlackRock increased its Outlook Therapeutics (OTLK) stake by 249% in Q2 2026, buying an estimated $739K and bringing the position to 1,668,579 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #4087.

BlackRock first reported a position in OTLK in Q2 2017 and has held it in 26 quarters since. The position peaked at $16M in Q2 2023. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • BlackRock held 1,668,579 shares of Outlook Therapeutics worth $2.65M as of Q2 2026.
  • BlackRock bought 1,191,108 Outlook Therapeutics shares in Q2 2026, an estimated $739K.
  • Outlook Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4087 holding.
  • BlackRock first reported a position in Outlook Therapeutics in Q2 2017 and has held it in 26 quarters since.
  • BlackRock's Outlook Therapeutics position peaked at $16M in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.